Oncology Patient Advocacy Spotlight
This week in health care trends, our oncology patient advocacy spotlight includes an analysis of drug pricing factors, a call to abandon fee-for-service, and a snapshot of New Jersey’s Medicaid ACOs.
The articles below are from our dedicated Oncology Patient Advocacy e-magazine. You can follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)
Amidst the continuing debate about financial toxicity and whether drug prices are based on their value or not, it’s helpful to have a sense of context. This in-depth article provides “a brief analysis of changes in the U.S. health care marketplace and how they may affect drug launch prices.”
Jimmy Carter — 39th President of the United States, humanitarian, and Nobel prize winner — recently announced that he has melanoma that has spread to his brain. Following this announcement, President Carter returned to his hometown of Plains, Georgia to teach Sunday school and drew quite a crowd of spectators.
This strong opinion piece argues that “the alternative payment models for primary care currently offered or being proposed by Medicare involve additional payments on top of fee-for-service. Like an addict, we seem unable to go “cold turkey” and instead insist on just a little of our drug. But this approach is bound to fail. If we truly want to move to a value-driven world and support a value-based payment model, we need to be willing to drop fee-for-service entirely.”
This article digs into how New Jersey has approached ACOs and what others can learn from their experiment and the interactions between their MMCOs (Medicaid Managed Care Organizations) and their Medicaid ACOs.